ELMMB logo
Facebook logo Twitter logo



Here you will find our Prescribing Guidelines. 

You can search for items using the search box or use the sub-category links.

Further information about our the development of our guidelines is available here

Overarching Policy for the Managed Introduction of New Drugs  
(Priority Setting of Medicines) - download using the link below
  • Priority Setting - Managed Introduction of New Drugs - Sept_v6.pdf [pdf / 1.30MB] East Lancashire Health Economy has a coordinated approach to managing medicines which is collaboration between NHS Blackburn with Darwen (BwD) Clinical Commissioning Group (CCG) NHS East Lancashire (EL) Clinical Commissioning Group (CCG) [collectively identified as Pennine Lancashire (PL CCGs) ] and East Lancashire Hospitals NHS Trust (ELHT). The overall aim is to take a Health Economy approach to the commissioning and use of medicines across the primary/secondary care interface, linking wi
Guidelines » Position Statements

Items In This Category

application/pdf7 day Prescription Policy Aug17 v2.pdf (256KB)26/09/2017Download
application/pdfAlogliptin Position Statement_0716.pdf (263KB)26/05/2017Download
application/pdfAntihistamines & nasal sprays for mild to moderate hayfever and allergic rhinitis Position statement (439KB)17/05/2019Download
application/pdfCamouflage creams and powders ELHE - Prescribing Policy v2.1 1219.pdf (886KB)11/12/2019Download
application/pdfCannabis Based Medicinal Products for Pain Position Statement_v1.1.pdf (262KB)25/02/2019Download
application/pdfDenosumab Position Statement Version 1.0.pdf (299KB)27/03/2018Download
application/pdfE-Cigarettes Position Statement v2 FINAL.pdf (251KB)01/11/2016Download
application/pdfEmpagliflozin Position Statement June 2017.pdf (347KB)30/06/2017Download
application/pdfEtanercept Biosimilar pos~ement (Version 1 (1).pdf (351KB)21/06/2016Download
application/pdfGeneric Biosimilar Position Statement Version 1.0 June-2017.pdf (241KB)21/07/2017Download
application/pdfGlucose Monitoring Devices Policy v1.2pdf (278KB)18/10/2018Download
application/pdfGluten Free Commissioning Statement for EL CCG/BwD CCG _2017.pdf (186KB)27/02/2017Download
application/pdfGolimumab Position Statement ELHE.pdf (443KB)21/06/2016Download
application/pdfInfliximab Biosimilar pos~ement (Version 1 (2).pdf (349KB)21/06/2016Download
application/pdfInsulin glargine biosimilar position statement Final pdf (342KB)05/10/2016Download
application/pdfJuvenile Idiopathic Arthritis in Adults Position Statement Version-1.0.docx .pdf (225KB)21/06/2016Download
application/pdfJuvenile Idiopathic Arthritis Policy for Adults Version-1.0.docx .pdf (225KB)21/06/2016Download
application/pdfLutein and Oral Antioxidant Vitamin (Eye Vitamins)_Position Statement_0619.pdf (486KB)09/07/2019Download
application/pdfNefopam Position Statement ELHE.pdf (285KB)18/04/2017Download
application/pdfNicotine Replacement Therapy Position Statement ELHE .pdf (209KB)08/03/2017Download
application/pdfNutritional Supplements in Substance MisuserV5.1_0917.pdf (352KB)26/09/2017Download
application/pdfOral Nutrition Supplements Prescribing for Care Home Residents.pdf ELHE (473KB)13/06/2017Download
application/pdfOTC items should not routinely be prescribed in primary care ELHE Policy.v1.1df (542KB)18/11/2020Download
application/pdfotc-guidance-for-ccgs.pdf (615KB)17/02/2020Download
application/pdfOut of area position statement-v2_ELHE.pdf (527KB)11/09/2019Download
Page: [1] [2]
[ Next » ]